Melany Worbes‐Cerezo
Research Subjects
Melany Worbes‐Cerezo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Keal
Adelphi Real World Bollington UK
1 shared publication - Alexander M. Litvintchouk
Johnson & Johnson Innovative Medicine United States Horsham Pennsylvania USA
1 shared publication - David Wu
Johnson & Johnson Innovative Medicine United States Horsham Pennsylvania USA
1 shared publication - Emily Goddard
Adelphi Real World, Bollington, UK
1 shared publication - James Hetherington
Adelphi Real World
1 shared publication - Sophie Barlow
Adelphi Real World, Bollington, UK
1 shared publication
Latest Publications
- Open Access
- 7 December 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (2) , 517-528
Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)
Background: Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available. Objectives: To assess diagnosis, treatment patterns and disease progression for patients diagnosed with mild‐to‐moderate PsO. Methods: Data were drawn from the Adelphi Real World PsO Disease Specific Programme, a cross‐sectional survey with retrospective data collection from dermatologists and their consulting adult PsO patients in France, Germany, Italy, Spain and the United Kingdom, conducted December 2021 to March 2022. Dermatologists reported on patient demographics and clinical characteristics at survey, diagnosis and treatment initiation. Patients self‐reported the impact of PsO on their quality of life. Results: Overall, 209 dermatologists provided data for 875 patients, with 356 (40.7%) providing self‐reported data. At initial presentation, 35.3% of patients were diagnosed with mild PsO, despite 79.7% of these patients having a BSA of 3%–10%. Further, 64.7% of patients were diagnosed with moderate PsO, although 62.8% had a BSA > 10%. Between diagnosis and current treatment initiation, patients diagnosed with mild PsO showed greater deterioration than those diagnosed with moderate PsO (mean relative BSA increase of 113.2 ± 307.2% compared to 17.7 ± 93.6%; p < 0.001). Most patients received topical therapy and/or phototherapy at diagnosis (mild: 94.9%, moderate: 85.5%; p < 0.001). Those diagnosed with moderate PsO were more likely to receive systemic treatments at diagnosis ( p < 0.001) and biologics at diagnosis and time of survey ( p = 0.029 and p < 0.001, respectively). Patients diagnosed with moderate PsO showed greater quality‐of‐life impact in the DLQI ( p = 0.006) and WPAI ( p = 0.002 and p = 0.006, respectively). Conclusions: Dermatologists may underestimate severity and treatment requirements in patients diagnosed with mild‐moderate PsO. Further research into PsO underdiagnosis and advanced treatment use in cases of mild PsO may provide better optimised treatment strategies.
- 7 December 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (2) , 517-528
Open AccessPatient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)
Background: Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available. Objectives: To assess diagnosis, treatment patterns and disease progression for patients diagnosed with mild‐to‐moderate PsO. Methods: Data were drawn from the Adelphi Real World PsO Disease Specific Programme, a cross‐sectional survey with retrospective data collection from dermatologists and their consulting adult PsO patients in France, Germany, Italy, Spain and the United Kingdom, conducted December 2021 to March 2022. Dermatologists reported on patient demographics and clinical characteristics at survey, diagnosis and treatment initiation. Patients self‐reported the impact of PsO on their quality of life. Results: Overall, 209 dermatologists provided data for 875 patients, with 356 (40.7%) providing self‐reported data. At initial presentation, 35.3% of patients were diagnosed with mild PsO, despite 79.7% of these patients having a BSA of 3%–10%. Further, 64.7% of patients were diagnosed with moderate PsO, although 62.8% had a BSA > 10%. Between diagnosis and current treatment initiation, patients diagnosed with mild PsO showed greater deterioration than those diagnosed with moderate PsO (mean relative BSA increase of 113.2 ± 307.2% compared to 17.7 ± 93.6%; p < 0.001). Most patients received topical therapy and/or phototherapy at diagnosis (mild: 94.9%, moderate: 85.5%; p < 0.001). Those diagnosed with moderate PsO were more likely to receive systemic treatments at diagnosis ( p < 0.001) and biologics at diagnosis and time of survey ( p = 0.029 and p < 0.001, respectively). Patients diagnosed with moderate PsO showed greater quality‐of‐life impact in the DLQI ( p = 0.006) and WPAI ( p = 0.002 and p = 0.006, respectively). Conclusions: Dermatologists may underestimate severity and treatment requirements in patients diagnosed with mild‐moderate PsO. Further research into PsO underdiagnosis and advanced treatment use in cases of mild PsO may provide better optimised treatment strategies.